Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.

Clicks: 333
ID: 102942
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #14 of 27 articles by views in chest

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
Reference Key
zhang2020treatmentchest Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhang, Bin;Liu, Shuyi;Tan, Tan;Huang, Wenhui;Dong, Yuhao;Chen, Luyan;Chen, Qiuying;Zhang, Lu;Zhong, Qingyang;Zhang, Xiaoping;Zou, Yujian;Zhang, Shuixing;
Journal chest
Year 2020
DOI
S0012-3692(20)30571-7
URL
Keywords
sars-cov-2 convalescent plasma critically illness

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.